Royalty Pharma plc

Royalty Pharma plc (NASDAQ: RPRX) engages in the acquisition of biopharmaceutical royalties and the provision of financial support for innovation within the biopharmaceutical sector. The company establishes partnerships with pioneers in this field, including those affiliated with academic institutions, research hospitals, and non-profit organizations, extending its reach from small to mid-cap biotechnology firms to large global pharmaceutical corporations.

Recent Financial and Business Updates:

• Fourth Quarter Income Statement Review:
  • Royalty Pharma’s total income and other revenues amounted to USD538.2 million for the three months ended June 30, 2023.
  • Operating income for the period was USD248.84 million, as compared to USD377.79 million in Q2 2022.
  • The basic earnings per Class A ordinary share amounted to USD0.51, while the diluted earnings per Class A ordinary share were USD0.50.
• Balance Sheet Review:
  • Royalty Pharma has cash and cash equivalents of USD2.17 billion as of June 30, 2023.
  • Total current assets as of June 30, 2023, amounted to USD2.95 billion.
  • Royalty Pharma’s total assets were USD17.12 billion by the end of June 2023.
  • Total shareholders’ equity as of June 30, 2023, was USD9.81 billion.
• Announced partnership:
  • Ascendis Pharma and Royalty Pharma plc have jointly revealed a financial arrangement wherein Ascendis Pharma has engaged in a capped synthetic royalty funding agreement worth USD150 million with Royalty Pharma.
  • This agreement is contingent upon the U.S. net SKYTROFA revenue.
  • In return for the payment of USD150, Ascendis Pharma agrees to pay Royalty Pharma a 9.15% royalty on the U.S. net SKYTROFA revenue, commencing on January 1, 2025.
  • These royalty payments to Royalty Pharma will conclude once they have received either 1.925 times the initial payment or 1.65 times that amount if received by December 31, 2031.

Technical Observation (on the daily chart)

Currently, the stock has undergone a correction of about 37.55% from its peak within the last 52 weeks, a milestone reached on December 01, 2022. In terms of technical indicators, the Relative Strength Index (RSI) reflects a value of 28.42 over a 14-day period, currently in oversold conditions. It's expected that there may be a period of consolidation or a potential of short-term upward movement. Furthermore, the stock's current price is situated below both the 21-day Simple Moving Average (SMA) and the 50-day SMA, which are widely recognized trend-following indicators. This placement underscores a bearish momentum in the short to medium term, and these moving averages may serve as active short-term resistance levels.

The stock's significant correction from its yearly high indicates a notable shift in investor sentiment, with the RSI pointing towards a potential stabilization or a short-term upward movement. However, the presence of these moving averages above the current price suggests that the stock faces resistance in its attempts to regain its previous levels.

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Buy’ rating has been given to Royalty Pharma plc (NASDAQ: RPRX) at its current market price of USD 27.77 as of September 18, 2023, at 07:30 am PDT. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing. 

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

How to Read the Charts?

The yellow colour line reflects the 21-period simple moving average (SMA) while the blue line indicates the 50- period simple moving average (SMA). SMA helps to identify existing price trends. If the prices are trading above the 21-period and 50-period moving average, then it shows prices are currently trading in a bullish trend.

The orange colour line in the chart’s lower segment reflects the Relative Strength Index (14-Period) which indicates price momentum and signals momentum in trend. A reading of 70 or above suggests overbought status while a reading of 30 or below suggests an oversold status.

The red and green colour bars in the chart’s lower segment show the volume of the stock. The volume is the number of shares that changed hands during a given day. Stocks with high volumes are more liquid than stocks with lesser volume as liquidity in stocks helps with easier and faster execution of the order.

The Orange colour lines are the trend lines drawn by connecting two or more price points and used for trend identification purposes. The trend line also acts as a line of support and resistance.

Technical Indicators Defined: -

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock. 

Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock. 

Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices. 

The reference date for all price data, currency, technical indicators, support, and resistance levels is September 18, 2023. The reference data in this report has been partly sourced from REFINITIV. 

Abbreviations

CMP: Current Market Price

SMA: Simple Moving Average

RSI: Relative Strength Index

USD: United States dollar 

Note: Trading decisions require a thorough analysis by individual. Technical reports in general chart out metrics that may be assessed by individuals before any stock evaluation. The above are illustrative analytical factors used for evaluating the stocks; other parameters can be looked at along with additional risks per se. Past performance is neither an indicator nor a guarantee of future performance.